Literature DB >> 15161761

Molecular alterations underlie nodal and paranodal degeneration in type 1 diabetic neuropathy and are prevented by C-peptide.

Anders A F Sima1, Weixian Zhang, Zhen-Guo Li, Yuichi Murakawa, Christopher R Pierson.   

Abstract

To explore the molecular abnormalities underlying the degeneration of the node of Ranvier, a characteristic aberration of type 1 diabetic neuropathy, we examined in type 1 BB/Wor and type 2 BBZDR/Wor rats changes in expression of key molecules that make up the nodal and paranodal apparatus of peripheral nerve. Their posttranslational modifications were examined in vitro. Their responsiveness to restored insulin action was examined in type 1 animals replenished with proinsulin C-peptide. In sciatic nerve, the expression of contactin, receptor protein tyrosine phosphatase beta, and the Na(+)-channel beta(1) subunit, paranodal caspr and nodal ankyrin(G) was unaltered in 2-month type 1 diabetic BB/Wor rats but significantly decreased after 8 months of diabetes. These abnormalities were prevented by C-peptide administered to type 1 BB/Wor rats and did not occur in duration- and hyperglycemia-matched type 2 BBZDR/Wor rats. The expression of the alpha-Na(+)-channel subunit was unaltered. In SH-SY5Y cells, only the combination of insulin and C-peptide normalized posttranslational O-linked N-acetylglucosamine modifications and maximized serine phosphorylation of ankyrin(G) and p85 binding to caspr. The beneficial effects of C-peptide resulted in significant normalization of the nerve conduction deficits. These data describe for the first time the progressive molecular aberrations underlying nodal and paranodal degenerative changes in type 1 diabetic neuropathy and demonstrate that they are preventable by insulinomimetic C-peptide.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15161761     DOI: 10.2337/diabetes.53.6.1556

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  19 in total

1.  Hyperpolarization of the membrane potential in cardiomyocyte tissue slices by the synchronization modulation electric field.

Authors:  Robin Dando; Zhihui Fang; Wei Chen
Journal:  J Membr Biol       Date:  2012-02-23       Impact factor: 1.843

2.  Reader's response to "advances in diabetes for the millennium: an e-symposium".

Authors:  Frances Burmeister
Journal:  MedGenMed       Date:  2005-01-20

3.  C-peptide is a bioactive peptide.

Authors:  J Wahren; K Ekberg; H Jörnvall
Journal:  Diabetologia       Date:  2007-01-18       Impact factor: 10.122

4.  Will C-peptide substitution make a difference in combating complications in insulin-deficient diabetes?

Authors:  Anders A F Sima
Journal:  Rev Diabet Stud       Date:  2004-08-10

5.  Sural nerve pathology in diabetic patients with minimal but progressive neuropathy.

Authors:  R A Malik; S Tesfaye; P G Newrick; D Walker; S M Rajbhandari; I Siddique; A K Sharma; A J M Boulton; R H M King; P K Thomas; J D Ward
Journal:  Diabetologia       Date:  2005-02-24       Impact factor: 10.122

6.  Degeneration of the Golgi and neuronal loss in dorsal root ganglia in diabetic BioBreeding/Worcester rats.

Authors:  H Kamiya; W Zhang; A A F Sima
Journal:  Diabetologia       Date:  2006-09-20       Impact factor: 10.122

7.  Dynamic changes of neuroskeletal proteins in DRGs underlie impaired axonal maturation and progressive axonal degeneration in type 1 diabetes.

Authors:  Hideki Kamiya; Weixian Zhang; Anders A F Sima
Journal:  Exp Diabetes Res       Date:  2009-10-12

Review 8.  Diabetic neuropathy: mechanisms to management.

Authors:  James L Edwards; Andrea M Vincent; Hsinlin T Cheng; Eva L Feldman
Journal:  Pharmacol Ther       Date:  2008-06-13       Impact factor: 12.310

9.  Coenzyme Q10 prevents peripheral neuropathy and attenuates neuron loss in the db-/db- mouse, a type 2 diabetes model.

Authors:  Tie-Jun Sten Shi; Ming-Dong Zhang; Hugo Zeberg; Johanna Nilsson; Jacob Grünler; Su-Xing Liu; Qiong Xiang; Jonas Persson; Kaj J Fried; Sergiu Bogdan Catrina; Masahiko Watanabe; Peter Arhem; Kerstin Brismar; Tomas G M Hökfelt
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-24       Impact factor: 11.205

Review 10.  Acetyl-L-carnitine in diabetic polyneuropathy: experimental and clinical data.

Authors:  Anders A F Sima
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.